For Q3, the fund's Retail Class shares gained 4.21%, lagging the 5.54% advance of the Composite index, a 50/50 blend of the S&P 500 index and the Bloomberg U.S. Aggregate Bond Index.
Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback